ENDOCRINE SOCIETY
OXFORD
The Endocrine Phenotype Induced by Pediatric Adrenocortical Tumors Is Age- and Sex-Dependent
Marina Kunstreich, 1,2[D Desiree Dunstheimer,1 Pascal Mier,2 Paul-Martin Holterhus,3 Stefan A. Wudy,4 Angela Huebner,5 Antje Redlich,2,*DD and Michaela Kuhlen1,*[D
1Paediatrics and Adolescent Medicine, Faculty of Medicine, University of Augsburg, Augsburg 86156, Germany
2Department of Paediatrics, Paediatric Haematology/Oncology, Otto-von-Guericke-University, Magdeburg 39120, Germany
3Department of Paediatrics, Division of Paediatric Endocrinology and Diabetes, Christian-Albrechts-University Kiel & University Hospital Schleswig-Holstein, Kiel 24105, Germany
4Paediatric Endocrinology & Diabetology, Steroid Research & Mass Spectrometry Unit, Centre of Child and Adolescent Medicine, Justus Liebig University, Giessen 35392, Germany
5Department of Paediatrics, Paediatric Endocrinology, University Hospital Dresden, Technische Universität Dresden, Dresden 01307, Germany
Correspondence: Michaela Kuhlen, MD, Paediatrics and Adolescent Medicine, University Medical Centre Augsburg, Stenglinstr. 2, Augsburg, 86156, Germany. Email: michaela.kuhlen@uk-augsburg.de.
*These authors contributed equally.
Abstract
Context: Adrenocortical carcinomas are very rare malignancies in childhood associated with poor outcome in advanced disease. Most adrenocortical tumors (ACT) are functional, causing signs and symptoms of adrenal hormone excess. In most studies, endocrine manifestations were reported 4 to 6 months prior to diagnosis.
Objective: We sought to extend knowledge on endocrine manifestations with regard to age and sex to facilitate early diagnosis.
Methods: We retrospectively analyzed features of adrenal hormone excess in children and adolescents with ACT registered with the GPOH- MET studies between 1997 and 2022. Stage of puberty was defined as prepubertal in females < 8 years of age and males < 9 years.
Results: By December 2022, 155 patients (110 female, 45 male) with data on endocrine manifestations had been reported. Median age at ACT diagnosis was 4.2 years [0.1-17.8], median interval from first symptoms was 4.2 months [0-90.7]. In 63 girls of prepubertal age, the most frequently reported manifestations were pubarche (68.3%), clitoral hypertrophy (49.2%), and weight gain (31.7%); in 47 pubertal female patients, the most frequent manifestations were excessive pubic hair (46.8%), acne (36.2%), and hypertension (36.2%). Leading symptoms in 34 boys of prepubertal age were pubarche (55.9%), penile growth (47.1%), and acne (32.4%), while in 11 pubertal male patients, leading symptoms were weight gain (45.5%), hypertension (36.4%), excessive pubic hair (27.3%), and cushingoid appearance (27.3%). In pubertal patients, symptoms of androgen excess were mainly unrecognized as part of pubertal development, while symptoms of Cushing syndrome were more frequently apparent.
Conclusion: The endocrine phenotype induced by pediatric ACT is age- and sex-dependent.
Key Words: adrenocortical tumor, children, endocrine, phenotype, Cushing syndrome, virilization, peripheral precocity
Abbreviations: ACA, adrenocortical adenoma; ACC, adrenocortical carcinoma; ACT, adrenocortical tumor; ACx, adrenocortical tumor of undetermined malignant potential; GPOH-MET, German Paediatric Oncology Haematology-Malignant Endocrine Tumour.
Adrenocortical tumors (ACTs) encompassing adrenocortical adenoma (ACA), tumors of undetermined malignant potential (ACx), and carcinoma (ACC) are very rare endocrine neo- plasms in children and adolescents (1-4). Pediatric ACT pre- sent with considerable clinical heterogeneity and ambiguous biological behavior impeding proper and timely diagnosis. Around half of pediatric patients are diagnosed with locally advanced tumors; in 50% of these patients, disease recurs even after complete tumor resection (5-8). Patients with meta- static disease have a dismal outcome, with an overall survival of less than 20% (9-11). The mainstay of therapy is complete surgical resection (12). Effective systemic therapies for
children and adolescents with advanced and metastatic dis- ease are still missing (13). Hence, identifying children and adolescents with ACT as early as possible is of crucial import- ance. However, a median symptomatic interval of 3 to 8 months prior to diagnosis was reported (9, 14, 15).
About 80% to 90% of pediatric ACT are functional, caus- ing signs and symptoms of adrenal hormone excess (14, 16). Nonfunctional tumors usually present as abdominal masses or less frequently as incidental findings (17, 18).
In published studies of children and adolescents with ACT, the phenotypic presentation of adrenal hormone excess was classi- fied into virilization (55.1%-61.0%), virilization combined
with Cushing syndrome (29.2%-39.2%), and Cushing syn- drome only (5.0%-53.5%) (19-21). These overarching groups of symptoms were reported to be associated with tumor stage (16). Virilization was more frequently reported in localized tu- mors, while Cushing syndrome was more frequently reported in cases with advanced and metastatic disease. Symptoms of ad- renal hormone excess were furthermore associated with out- come (22). Being affected by Cushing syndrome resulted in worse outcome compared with being not affected by Cushing syndrome. Non-secreting tumors were also associated with poor outcome. Notably, Cushing syndrome and non-secreting tumors were more frequently diagnosed in older children (20).
Here, we seek to extend our knowledge on and deepen our understanding of signs and symptoms of adrenal hormone ex- cess in children and adolescents with ACT. To this end, we as- sessed the spectrum of endocrine manifestations in children and adolescents with ACT registered with the German Paediatric Oncology Haematology-Malignant Endocrine Tumour (GPOH-MET) studies since 1997. We asked if the endocrine phenotype was associated with age, sex, and tumor dignity and if there were features that should raise attention.
Methods
The GPOH-MET studies prospectively registered children and adolescents < 18 years of age (subsequently referred to as pediat- ric) with ACT. Patients were reported by the treating physicians in Germany, Austria, and Switzerland upon informed consent of patients, parents, and legal guardians, as appropriate. We in- cluded patients with information on endocrine manifestations at diagnosis of ACT, registered between 1997 and 2022.
The GPOH-MET 97 protocol and registry were approved by the ethics committees of the University of Luebeck (Approval number 97125) and Otto-von-Guericke-University Magdeburg (Approval number 174/12), Germany.
Demographic-, endocrine-, and tumor-related characteris- tics were collected using original source data. Frequencies were related to cases with recorded data. On the case report form, endocrine manifestations were categorized into viriliza- tion, Cushing syndrome, hypertension, abdominal pain, other symptoms, and no symptoms. Details on endocrine manifesta- tions, including premature axillary and/or pubic hair (herein referred to as pubarche), clitoral hypertrophy, menstrual dis- order, hirsutism, penile growth, deepening of voice, tall stat- ure, accelerated bone age, increased muscle strength, alopecia, acne, sweat odor, greasy hair, weight gain/obesity, hypertension, tiredness”, reduced performance”, weakness”, headache* (*herein referred to as tiredness), dizziness+, nau- sea+ and vomiting+ (+herein referred to as dizziness) were col- lected from free-text entries. In addition, data on pain, neurologic, and pulmonary symptoms were analyzed.
For this analysis, we defined stage of puberty as prepubertal in female patients <8 years of age and in male patients < 9 years of age and pubertal in all other cases, in correspond- ence with current definitions (23). We re-categorized signs and symptoms of phenotypic endocrine manifestations as follows: In prepubertal girls, the presence of pubic hair (without the- larche), clitoral hypertrophy, hirsutism, deepening of voice, menstrual disorder, acne, greasy hair, sweaty odor, increased muscle strength, accelerated bone age and tall stature was de- fined as virilization. Pubic hair was classified as “excessive” in pubertal patients (herein defined by age) if reported in the case report form. In prepubertal boys, peripheral precocity was
defined in the presence of any of the following features: pubic hair, penile growth, deepening of voice, acne, greasy hair, hir- sutism, sweaty odor, increased muscle strength, accelerated bone age, and tall stature. Cushing syndrome was defined in the presence of any of the following features: cushingoid ap- pearance including moon face, buffalo hump and/or striae, hirsutism, acne, mood swing, weight gain/obesity, growth dis- order, hypertension, tiredness, and menstrual disorder.
All reported endocrine manifestations were re-reviewed by the authors (Ma.Ku, D.D., and M.K.) and re-classified accord- ing to Fig. 1. Patients were classified as mixed phenotype in case signs and symptoms of virilization (female)/peripheral precocity (male) and Cushing syndrome were present and in case of overlapping syndromes of virilization (female)/periph- eral precocity (male) and Cushing syndrome.
Laboratory findings (plasma and/or urinary steroid hor- mone profiles) were reviewed to corroborate the endocrine phenotype. The GPOH-MET protocol did not provide central measurement of steroid hormone profiles, but the registry rec- ommended central measurements of plasma (P.M.H.) and urinary steroid hormone profiles (S.A.W.) since 2013. Nevertheless, various methods and approaches were used due to the multicenter design of the study and period in time. For this analysis, we accepted steroid hormone measure- ments from local laboratories and their interpretation accord- ing to local reference ranges.
Statistical Analyses
Differences between groups were determined by the log-rank or chi-squared test or Mann-Whitney- U test and t test as appropri- ate. A P value of <. 05 was considered significant. Differences in the distribution of sexes were calculated in comparison with population-based data using the Genesis database as of December 31, 2019. Survival probabilities were estimated using the Kaplan-Meier method. Event-free survival (EFS) was defined as the time from diagnosis to first event, defined as progression, relapse, or death of disease, whichever occurred first. Survivors were censored at the date of last follow-up. Data were analyzed using IBM SPSS statistical package (version 29.0.0.0).
Results
A total of 155 children and adolescents with ACT [ACA n = 47 (30.3%), ACx n = 19 (12.3%), and ACC n = 89 (57.4%)] were included, with a median age at diagnosis of 4.2 years (range, 0.1-17.8). Sex ratio demonstrated a female preponderance [110 (71.0%) female, 45 (29.0%) male, P = <. 001]. Distant me- tastases were present in 19 of 108 (17.6%) patients with ACC/ ACx. Demographic characteristics are detailed in Table 1.
A median interval of endocrine symptoms prior to diagnosis of ACT of 4.2 months (range, 0-90.7) was reported. In 70 (of 155; 45.2%) patients, virilization (female)/peripheral preco- city (male) was reported; in 18 (11.6%) patients, Cushing syn- drome; and in 33 (21.3%) patients, a mixed phenotype with virilization (female)/peripheral precocity (male) and Cushing syndrome. The absence of endocrine manifestations was re- ported in 34 (21.9%) patients.
Phenotypic Endocrine Manifestations of ACT in Prepubertal and Pubertal Female Patients
Of 110 females, 63 (57.2%) patients were prepubertal accord- ing to age. The median interval of endocrine symptoms prior
Virilisation (female) Peripheral precocity (male)
Cushing’s syndrome
Overlap
Pubarche/excessive pubic hair Clitoral hypertrophy Penile growth Tall stature Sweat odor
Menstrual disorder Acne Hirsutism
Cushingoid appearance Weight gain/obesity Hypertension Tiredness Dizziness Mood Swings
Deep voice Greasy hair
| Female | Male | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| <8 years (n = 63) | % | ≥ 8 years (n = 47) | % | <9 years (n = 34) | % | ≥ 9 years (n=11) | % | ||
| Diagnosis | |||||||||
| ACC | 29 | 46.0 | 31 | 66.0 | 22 | 64.7 | 7 | 63.6 | |
| ACA | 24 | 38.1 | 13 | 27.7 | 6 | 17.6 | 4 | 36.4 | |
| ACx | 10 | 15.9 | 3 | 6.4 | 6 | 17.6 | 0 | ||
| Age at diagnosis (years) | |||||||||
| Median | 1.6 | 13.7 | 2.0 | 13.3 | |||||
| Range | 0.1-7.5 | 8.3-17.1 | 0.2-8.2 | 9.0-17.8 | |||||
| Interval of endocrine symptoms | prior to | ||||||||
| diagnosis (months) | |||||||||
| Median | 3.6 | 6.5 | 3.6 | 9.0 | |||||
| Range | 0-61.3 | 0.7-90.6 | 0-29.8 | 0.4-60.0 | |||||
| Endocrine phenotypeª | |||||||||
| Virilization | 39 | 61.9 | 17 | 36.2 | 15 | 44.1 | |||
| Cushing | 5 | 7.9 | 8 | 17.0 | 3 | 8.8 | 2 | 18.2 | |
| Mixed | 11 | 17.5 | 12 | 25.5 | 6 | 17.6 | 3 | 27.3 | |
| Silent | 8 | 12.7 | 10 | 21.3 | 10 | 29.4 | 6 | 54.5 | |
| Tumor volume (mL) | |||||||||
| Median | 75.0 | 300.7 | 101.3 | 156.0 | |||||
| Range | 0.5-1260.0 | 2.5-2907.0 | 4.0-1254.0 | 9.0-3645.0 | |||||
| Distant metastases in ACC/ACx | |||||||||
| No | 28 | 71.8 | 16 | 47.1 | 19 | 67.9 | 3 | 42.9 | |
| Yes | 1 | 2.6 | 11 | 32.4 | 4 | 14.3 | 3 | 42.9 | |
| No data | 10 | 25.6 | 7 | 20.6 | 5 | 17.9 | 1 | 14.3 | |
“Grouping as reported in the case report form.
to ACT diagnosis in female was 4.2 months (range, 0-90.6). Details on endocrine manifestations are given in Table 2.
The most frequent endocrine manifestations in 63 pre- pubertal females are depicted in Fig. 2A. Of 43 patients with pubarche, 26 (60.5%) patients additionally presented with clitoral hypertrophy, 9 (20.9%) patients with clitoral hyper- trophy and acne, and 7 (16.3%) patients with clitoral hypertrophy and tall stature. The most frequent symptom
combinations are depicted in Fig. 3A. Thelarche was not re- ported in any prepubertal girl. In 8 (12.7%) of 63 patients, clinical signs and symptoms were reported to be nonexisting.
The most frequently reported endocrine signs and symp- toms in 47 pubertal females are illustrated in Fig. 2B. Of 22 patients with excessive pubic hair, 13 (59.1%) additionally presented with acne, 6 (27.3%) with acne and hirsutism, and 4 (18.2%) with acne and menstrual disorders (Fig. 3B).
| Female | Male | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <8 years (n = 63) | % | ≥ 8 years (n = 47) | % | P value | <9 years (n = 34) | % | ≥ 9 years (n= 11) | % | P value | |
| Virilization (female)/peripheral precocity (male) | ||||||||||
| Pubarche/excessive pubic hair | 43 | 68.3 | 22 | 46.8 | .024 | 19 | 55.9 | 3 | 27.3 | .166 |
| Clitoral hypertrophy | 31 | 49.2 | 6 | 12.8 | <. 001 | — | — | — | ||
| Penile growth | — | — | — | 16 | 47.1 | 1 | 9.1 | .024 | ||
| Tall stature | 14 | 22.2 | 4 | 8.5 | .051 | 7 | 20.6 | 1 | 9.1 | .328 |
| Sweat odor | 10 | 15.9 | 7 | 14.9 | .985 | 4 | 11.8 | 1 | 9.1 | .704 |
| Deep voice | 4 | 6.3 | 12 | 25.5 | .007 | 3 | 8.8 | 0 | 0.0 | .298 |
| Greasy hair | 5 | 7.9 | 2 | 4.3 | .519 | 2 | 5.9 | 0 | 0.0 | .367 |
| Overlapping signs and symptoms of virilization (female)/peripheral precocity (male) and Cushing syndrome | ||||||||||
| Menstrual disorder (sec. amenorrhea) | 1 | 1.6 | 11 | 23.4 | <. 001 | — | — | |||
| Acne | 14 | 22.2 | 17 | 36.2 | .110 | 11 | 32.4 | 1 | 9.1 | .087 |
| Hirsutism | 3 | 4.8 | 9 | 19.1 | .017 | 1 | 2.9 | 0 | 0 | .565 |
| Cushing syndrome | ||||||||||
| Cushingoid appearance | 3 | 4.8 | 5 | 10.6 | .240 | 3 | 8.8 | 3 | 27.3 | .118 |
| Weight gain/obesity | 20 | 31.7 | 16 | 34.0 | .915 | 8 | 23.5 | 5 | 45.5 | .153 |
| Hypertension | 13 | 20.6 | 17 | 36.2 | .075 | 7 | 20.6 | 4 | 36.4 | .372 |
| Tirednessª | 9 | 14.3 | 16 | 34.0 | .022 | 6 | 17.6 | 2 | 18.2 | .924 |
| Dizzinessb | 2 | 3.2 | 8 | 17.0 | .014 | 4 | 11.8 | 1 | 9.1 | .704 |
| Mood swings | 4 | 6.3 | 1 | 2.1 | .293 | 1 | 2.9 | 1 | 9.1 | .390 |
| No endocrine signs and symptoms | ||||||||||
| Phenotypic silent | 8 | 12.7 | 8 | 17.0 | .494 | 10 | 29.4 | 4 | 36.4 | .665 |
| Other symptoms | ||||||||||
| Abdominal/back pain | 6 | 9.5 | 12 | 25.5 | .028 | 3 | 8.8 | 6 | 54.5 | .003 |
“Including reduced performance, weakness, and headache.
“Including nausea and vomiting.
In 8 (17.0%) of 47 patients, the absence of any endocrine manifestation was reported. In addition, 12 (25.5%) pubertal females presented with abdominal/back pain.
Clitoral hypertrophy (P <. 001) and pubarche (P =. 024) were more frequently present in prepubertal compared to pubertal female. Deep voice (P =. 007), menstrual disorders (P <. 001), dizziness (P =. 014), tiredness (P =. 022), and ab- dominal/back pain (P = . 028) were more frequent in pubertal compared to prepubertal female.
No differences were observed in body mass index in pre- pubertal and pubertal patients compared to age-adjusted data from the KiGGS study (24).
Of 110 female patients, 2 prepubertal and 2 pubertal patients presented with neurologic symptoms, including posterior revers- ible encephalopathy syndrome, focal neurologic signs, and seiz- ures (due to hyponatremia in 1 patient). Four pubertal patients presented with respiratory symptoms due to pulmonary metas- tases and pulmonary and cardiogenic embolism.
Phenotypic Endocrine Manifestations of ACT in Prepubertal and Pubertal Male Patients
Of 45 males, 34 (75.5%) patients were prepubertal according to age. The median interval from first endocrine signs and symptoms to ACT diagnosis was 3.9 months (range, 0-60.0).
Leading endocrine signs and symptoms of adrenal hormone excess in 34 prepubertal males are illustrated in Fig. 2C. Of 19
patients with pubarche, 16 (84.2%) additionally presented with penile growth, 9 (47.4%) with penile growth and acne, and 4 (21.1%) with penile growth and weight gain/obesity (Fig. 3C).
The leading endocrine symptoms in 11 pubertal male patients are depicted in Fig. 2D. Of 5 patients with weight gain/obesity, 3 (60.0%) additionally presented with cushingoid appearance, and 2 (40.0%) with cushingoid appearance and tiredness (Fig. 3D). In 4 (36.4%) of 11 pubertal male patients, the absence of any endocrine manifestation was reported. In addition, ab- dominal/back pain was reported in 54.5% of patients, thereby being the most frequent symptom in pubertal male.
Penile growth was more frequent in prepubertal compared to pubertal male (P =. 024), whereas pain was more frequent- ly reported in pubertal compared to prepubertal patients (P =. 003).
Clinical Manifestations in Prepubertal Compared to Pubertal Patients
Genital changes, including clitoral hypertrophy and penile growth (P <. 001), pubarche (P =. 024), and tall stature (P =. 031) were more frequently reported in prepubertal pa- tients compared to pubertal patients. Deep voice (P =. 016), hirsutism (P =. 012), hypertension (P =. 042), abdominal/ back pain (P <. 001), and tiredness (P =. 037) were more fre- quent in pubertal compared to pubertal patients (Fig. 2E and 2F). No difference was observed for cushingoid appearance
A
B
36,2%
36,2%
68,3%
46,8%
49,2%
31,7%
♀
C
D
36,4%
32,4%
+
27,3%
9)
55,9%
27,3%
47,1%
45,5%
U
♂
E
F
OM
20,7%
15,5%
21,6%
E
31,0%
63,9%
36,2%
48,5%
31,0%
♀
♂
♀
♂
(P =. 110). The interval from onset of first symptoms to ACT diagnosis was shorter in prepubertal compared to pubertal pa- tients (P =. 015).
Phenotypic Endocrine Manifestations and Laboratory Findings
Next, we looked in more detail at those 106 of 155 (68.4%) patients for whom data on laboratory findings of androgens und glucocorticoids were available. To this end, we first re- classified endocrine signs and symptoms as virilization (fe- male)/peripheral precocity (male), Cushing syndrome, mixed phenotype, and silent endocrine phenotype as described in the “Methods” section (Fig. 4).
Clinical diagnosis of virilization (female)/peripheral preco- city (male) was confirmed by laboratory findings in 62 (of 63; 98.4%) girls and 22 (of 22; 100%) boys, whereas clinical diagnosis was not confirmed by laboratory findings in 1 (1.6%) girl. The median number of symptoms of virilization (female)/peripheral precocity (male) was 3 [1-7].
Laboratory findings confirmed clinical diagnosis of Cushing syndrome in 69 (of 71; 97.2%) patients. In those patients, the median number of symptoms of the Cushing syndrome com- plex was 2 [1-5]. In another 24 patients without any sign or symptom of Cushing syndrome, laboratory findings demon- strated elevated cortisol levels.
Of 9 patients with clinical silent endocrine phenotypes, 3 (of 5; 60.0%) female and 3 (of 4; 75.0%) male were identified with elevated androgen levels. In 2 (of 5; 40.0%) female pa- tients and 1 (of 4; 25%) male patient, the absence of any sign or symptom of the Cushing syndrome complex was cor- roborated by normal cortisol levels.
In 55 patients with a mixed endocrine phenotype on the basis of laboratory findings, overlapping symptoms of virilization (female)/peripheral precocity (male) and Cushing syndrome were present in 41 (77.4%) patients. In those patients, the me- dian number of presenting symptoms was 5 [1-10].
In addition, laboratory findings identified hyperaldosteron- ism in 4 females with hypertension and elevated estrogen levels in one pubertal male with gynecomastia and “feminization.”
Endocrine Phenotype and Tumor Features
We further looked at endocrine manifestations and tumor fea- tures in more detail. The most frequent symptoms in patients of prepubertal age with ACA were pubarche (17; 56.7%), weight gain/obesity (12; 40.0%), and clitoral hypertrophy/penile growth (10; 33.3%), whereas pubarche (37; 72.5%), clitoral hypertrophy/penile growth (29; 56.9%), and acne (16; 31.4%) were most frequent in patients with ACC. In pubertal patients with ACA, the most frequent symptoms were excessive pubic hair (8; 47.1%), weight gain/obesity (5; 29.4%), and sweat odor or deep voice (4 each; 23.6%), while in patients with ACC, the most frequent symptoms were hypertension (19; 50.0%), excessive pubic hair (16; 42.1%), and weight gain/obes- ity and tiredness (15 each; 39.5%). Penile growth (P = . 008) and acne (P =. 028) were more frequently reported in patients with ACC compared to ACA. We also observed a trend toward more frequent genital changes (clitoral hypertrophy in female and penile growth in male combined) (P =. 066) and tiredness (P =. 084) in patients with ACC compared to patients with ACA. No differences were observed for other endocrine manifes- tations, including cushingoid appearance.
We next compared endocrine manifestations in 89 ACC pa- tients with and without metastases at initial diagnosis. Clitoral hypertrophy (P = . 015) was more frequently reported in patients without metastatic disease, while hypertension (P =. 003) was more frequently observed in patients with
A
B
우
< 8 years
9
≥ 8 years
43 patients
22 patients
60,5%
18,2%
20,9%
59.1%
2
27,3%
16,3%
E *
37,2%
20,9%
45,5%
1
4,0%
16,3%
31,8%
31,8%
J
+
C
D
< 9 years
3
≥ 9 years
47,4%
19 patients
84,2%
5 patients
60,0%
40,0%
36,8%
+
E *
57,9%
60,0%
15,8%
15,8%
40,0%
9
3
7%
13%
32%
17%
51%
57%
13%
10%
metastases. No differences were observed for other endocrine manifestations. In addition, no differences were observed for endocrine manifestations in ACC patients with Ki67-index < 15% compared to Ki67-index ≥ 15%.
Discussion
To the best of our knowledge, this is the first comprehensive analysis of the various endocrine manifestations in 155 chil- dren and adolescents with ACT. The latency from first endo- crine symptoms to ACT diagnosis was 4.8 months (range, 0-90.7), in line with previous reports (3.0-8.1 months) (14, 15). Our data demonstrate that the endocrine phenotype is age- and sex-dependent. It is not associated with tumor dig- nity. The most frequent overarching endocrine phenotype is mixed (virilization/peripheral precocity combined with Cushing syndrome; 53.8%), followed by virilization/periph- eral precocity (27.9%), and Cushing syndrome (11.5%), which has previously been reported (11, 20, 25).
In patients of prepubertal age, endocrine manifestations were predominantly shaped by the effects of androgen hormone ex- cess causing signs and symptoms of virilization/contrasexual per- ipheral precocity in females and isosexual precocity (eg, pubarche, penile growth) in males. The absence of premature thelarche supported the isolated activation of the adrenals, with the consequent manifestations of excessive androgens and/corticosteroids production, but not of the ovaries. In add- ition, some patients of prepubertal age presented with signs and symptoms of Cushing syndrome (eg, weight gain, acne, hypertension) caused by hypercortisolism. However, clinical diagnosis of Cushing syndrome was challenging in some cases for 3 reasons: (i) various definitions of Cushing syndrome are used in the literature (16, 26); (ii) there is an overlap of signs and symptoms of Cushing syndrome and virilization (female)/ peripheral precocity (male) (Fig. 1); and (iii) endocrine manifes- tations consistent with Cushing syndrome were frequently “un- specific” such as hypertension, acne, and weight gain, whereas “typical” symptoms of Cushing syndrome, such as moon face and buffalo hump, were less frequently reported. It should not go unmentioned that hypertension may be caused by vascular compression due to local tumor growth. However, only 2 of 41 hypertensive patients in our cohort presented with isolated hypertension.
On the other hand, in patients of pubertal age, the clinical ef- fects of androgen hormone excess were less striking, shaping a different, less distinctive endocrine phenotype of virilization or puberty, including acne and excessive pubic hair in both sexes. Notably, these symptoms again overlap with clinical Cushing features. Cushing syndrome was more frequently diagnosed in pubertal patients and, thus, may be clinically more apparent.
Despite common usage in oncologic reports, our data clearly demonstrate that virilization is too unspecific to characterize the various effects of adrenal hormone excess in pediatric patients with ACT. In fact, excessive pubic hair was the leading manifest- ation in both sexes and all ages. Clitoral hypertrophy was only affecting prepubertal females. Male and pubertal female rather presented with symptoms of the Cushing syndrome complex.
Intimate knowledge of the multi-faceted endocrine pheno- types in children and adolescents with ACT is of particular importance for early diagnosis. We demonstrated that in pedi- atric patients with ACT, excessive pubic hair was the most fre- quent symptom (73 of 155 patients), including 4 patients with this as the only symptom. According to recent guidelines,
isolated premature pubarche only implies follow-up within 3 months (27). From our point of view, this needs to be dis- cussed. An ultrasound examination and urinary steroid hor- mone profile are simple, affordable, and without side effects but facilitate identification of pediatric patients with ACT as early as possible. Noteably, in 80.3% of patients of prepuber- tal age at least 2 symptoms of (precocious) androgenization were present. However, it should not go unmentioned that data on bone age and growth rate were not available, repre- senting the most important limitation of our study. In endocri- nologic recommendations for diagnostic workup in pediatric patients with signs and symptoms of peripheral precocity and other conditions associated with adrenal hypersecretion (28), these are important parameters with implications for further management. Adrenal hypersecretion can often lead to precocious closure of growth plates in long bones and, therefore, change the growth curve, and finally, determine short stature, among other side effects. Some of the multiple signs and symptoms of Cushing syndrome (eg, hypertension, weight gain, acne) were frequently present, particularly in pu- bertal patients. However, Cushing syndrome was undiag- nosed in a number of patients in our study, most likely in patients of prepubertal age with signs and symptoms of viril- ization (female)/peripheral precocity (male) which overlap with Cushing syndrome. In some cases, indeed, Cushing syn- drome was clinically overlooked or only substantiated by the detection of excessive cortisol levels. In line with this, the phenotypic endocrine manifestations did not entirely reflect the tumor’s hormonal secretory profile in some cases. Nonetheless, increased attention to Cushing syndrome in the context of ACT is important for predicting prognosis and risk stratification (12).
Our data demonstrate that the endocrine phenotype does not predict tumor dignity. However, we observed a trend to more severe endocrine symptoms in patients with ACC. We previously reported that the tumor volume of pediatric pa- tients with ACC compared to patients with ACA is significant- ly increased (29). Supported by our data we hypothesize that the endocrine phenotype is predominantly shaped by the ad- renal hormone excess caused by hormone producing tumor cells rather than tumor dignity.
Our analysis has several limitations including its retrospect- ive character, data availability, and various methods used for laboratory testing:
· Data on stage and pace of pubertal development including bone age, growth rate, and testicular volume were not available.
· Analysis of the evolution of endocrine manifestations over time including severity was not possible.
· Laboratory results were only categorically reported, de- tails on methods and pre-test circumstances were not available. Specifically, detailed data on cortisol at mid- night saliva, 8 AM blood or 24-hour urinary collection and/or altered suppression tests and type were not avail- able. However, this information is important as the ap- proach and cutoffs of Cushing diagnosis, especially in younger children, is still debated.
· Important limitations in frequency assessment due to data availability.
Nevertheless, our data highlight the various endocrine phe- notypes in children and adolescents with ACT and raise
awareness to the multi-faceted signs and symptoms of this very rare pediatric malignancy.
Conclusion
The endocrine phenotype in children and adolescents with ACT is age- and sex-dependent but not associated with tumor dignity. In prepubertal patients the phenotype is predominant- ly shaped by signs and symptoms of androgen hormone excess. In pubertal patients this is less obvious while abdominal/back pain and symptoms of Cushing syndrome are more apparent.
Acknowledgments
Parts of this work were presented as a poster presentation at the JA-PED 2023, Ulm, Germany, November 2-4, 2023. The engaging infographics and illustrations were created and graphically designed by Kolja Kunstreich.
Funding
The German MET studies were funded by Deutsche Kinderkrebsstiftung, grant number DKS 2014.06, DKS 2017.16, DKS 2021.11, W.A. Drenckmann Stiftung, Mitteldeutsche Kinderkrebsstiftung, and Magdeburger Förderkreis krebskranker Kinder e.V. A.H. was supported by Deutsche Forschungsgemeinschaft (Germwithin the CRC/Transregio 205/2 (314061271-TRR-205).
Disclosures
The authors have no conflicts of interest to declare.
Data Availability
The data presented in this study are available upon reasonable request from the corresponding author. The data are not pub- licly available due to restrictions.
References
1. Dall’Igna P, Virgone C, De Salvo GL, et al. Adrenocortical tumors in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries. J Pediatr Surg. 2014;49(9): 1367-1371.
2. Siegel DA, King J, Tai E, Buchanan N, Ajani UA, Li J. Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009. Pediatrics. 2014;134(4):e945-e955.
3. McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: a surveillance, epidemiology, and end re- sults (SEER) program study. J Pediatr Surg. 2013;48(5):1025-1031.
4. Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumors. JClinEndocrinolMetab. 1997;82(7):2027-2031.
5. Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The international pediatric adrenocortical tumor registry initiative: con- tributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. MolCell Endocrinol. 2012;351(1):37-43.
6. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, Ribeiro RC. Biology, clinical characteristics, and management of adrenocort- ical tumors in children. PediatrBlood Cancer. 2005;45(3):265-273.
7. Gulack BC, Rialon KL, Englum BR, et al. Factors associated with sur- vival in pediatric adrenocortical carcinoma: an analysis of the nation- al cancer data base (NCDB). J Pediatr Surg. 2016;51(1):172-177.
8. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian registry for adrenal cortical carcinoma: analysis of a multi- institutional series of 129 patients. The ACC Italian registry study group. Surgery. 1996;119(2):161-170.
9. Kuhlen M, Kunstreich M, Wudy SA, et al. Outcome for pediatric adreno-cortical tumors is best predicted by the COG stage and five-item microscopic score-report from the German MET studies. Cancers (Basel). 2022;15(1):225.
10. Cecchetto G, Ganarin A, Bien E, et al. Outcome and prognostic factors in high-risk childhood adrenocortical carcinomas: a report from the European cooperative study group on pediatric rare tumors (EXPERT). Pediatr Blood Cancer. 2017;64(6).
11. Picard C, Faure-Conter C, Leblond P, et al. Exploring heterogeneity of adrenal cortical tumors in children: the French pediatric rare tumor group (fracture) experience. Pediatr Blood Cancer. 2020;67(2): e28086.
12. Zambaiti E, Duci M, De Corti F, et al. Clinical prognostic factors in pediatric adrenocortical tumors: a meta-analysis. Pediatr Blood Cancer. 2021;68(3):e28836.
13. Kuhlen M, Kunstreich M, Lessel L, et al. Refractory and relapsed paediatric ACC in the MET studies-a challenging situation neces- sitating novel diagnostic and therapeutic concepts. EJC Paediatr Oncol. 2023;1:100015.
14. Ciftci AO, Senocak ME, Tanyel FC, Buyukpamukcu N. Adrenocortical tumors in children. JPediatrSurg. 2001;36(4):549-554.
15. Gupta N, Rivera M, Novotny P, Rodriguez V, Bancos I, Lteif A. Adrenocortical carcinoma in children: a clinicopathological ana- lysis of 41 patients at the Mayo Clinic from 1950 to 2017. Horm Res Paediatr. 2018;90(1):8-18.
16. Rodriguez-Galindo C, Krailo MD, Pinto EM, et al. Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children’s oncology group ARAR0332 protocol. J Clin Oncol. 2021;39(22):2463-2473.
17. Singh P, Sharma P, Rana S, Daiya S, Sangwaiya A. Non-functioning adrenocortical carcinoma (incidentaloma)-a case report and review of literature. J Case Rep. 2014;2(5):503.
18. Chen Q-L, Su Z, Li Y-H, Ma H-M, Chen H-S, Du M-L. Clinical characteristics of adrenocortical tumors in children. J Pediatr Endocrinol Metab. 2011;24(7-8):535-541.
19. Martins-Filho SN, Almeida MQ, Soares I, et al. Clinical impact of pathological features including the Ki-67 labeling index on diagno- sis and prognosis of adult and pediatric adrenocortical tumors. Endocr Pathol. 2021;32(2):288-300.
20. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and out- come characteristics of children with adrenocortical tumors: a re- port from the international pediatric adrenocortical tumor registry. JClinOncol. 2004;22(5):838-845.
21. Wang Z, Liu G, Sun H, et al. Clinical characteristics and prognosis of adrenocortical tumors in children. Pediatr Surg Int. 2019;35(3): 365-371.
22. Riedmeier M, Decarolis B, Haubitz I, et al. Adrenocortical carcinoma in childhood: a systematic review. Cancers (Basel). 2021;13(21):5266.
23. Hauffa BP, Heger S. Pädiatrische Endokrinologie und Diabetologie. Springer; 2020:323350.
24. Robert Koch-Institut, Abteilung für Epidemiologie und Gesundheitsmonitoring. Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS-Basiserhebung). Scientific Use File 5. Version. 2019. Doi:10.7797/9-200306-1-1-5
25. Ribeiro RC, Figueiredo B. Childhood adrenocortical tumours. Eur J Cancer. 2004;40(8):1117-1126.
26. Bertagna X, Guignat L, Groussin L, Bertherat J. Cushing’s disease. Best Pract Res Clin Endocrinol Metab. 2009;23(5):607-623.
27. Klein DA, Emerick JE, Sylvester JE, Vogt KS. Disorders of puberty: an approach to diagnosis and management. Am Fam Physician. 2017;96(9):590-599.
28. Carel JC, Léger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22):2366-2377.
29. Kuhlen M, Pamporaki C, Kunstreich M, et al. Adrenocortical tu- mors and pheochromocytoma/paraganglioma initially mistaken as neuroblastoma-experiences from the GPOH-MET registry. Front Endocrinol (Lausanne). 2022;13:918435.